Login
BOSTON SCIENTIFIC CORP logo

BOSTON SCIENTIFIC CORP

bostonscientific.com

What Do They Do?

Develops and sells medical devices used by physicians and other medical professionals to diagnose and treat cardiovascular, digestive, neurological and urological conditions.

How Do They Make Money?

Interventional Cardiology & Vascular Therapies is the largest business; U.S. customers typically pay for devices within 30 days. Consigned products count as sold when used or implanted, while some heart-monitoring services are paid over the service period.

revenue
SegmentShareRevenue
Endoscopy
Sold outright

15%
FY2022: 18%
Urology
Sold outright

14%
FY2022: 14%
Neuromodulation
Sold outright
6.0%
FY2022: 7.2%
Interventional Cardiology & Vascular Therapies
Sold outright

23%
Watchman
Sold outright

9.8%
FY2022: 8.0%
Electrophysiology
Sold outright

17%
FY2022: 4.6%
Cardiac Rhythm Management
Mix

12%
FY2022: 17%
Interventional Oncology & Embolization
Sold outright
5.0%

Who Are Their Customers?

It sells devices to hospitals, clinics, outpatient facilities and medical offices, mainly through direct sales teams; distributors and dealers serve some international markets. Group purchasing organizations, hospital networks and other buying groups also represent a substantial part of sales.

Do Revenues Turn Into Profits?

Yes. It kept 14 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.

Operating income, FY2025
18% of revenue
▲ +39% vs FY2024 ($2.6B, 16%)
Net income, FY2025
14% of revenue
▲ +56% vs FY2024 ($1.9B, 11%)
Free cash flow, FY2025
18% of revenue
▲ +38% vs FY2024 ($2.6B, 16%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +1%
vs $5.1B in Q3 FY2025
Net income
▼ −23%
vs $755M in Q3 FY2025
  • Aug 26, 2026 Cyber incident disrupts global operations The incident disrupted systems used to process and ship customer orders; the timing of full restoration and the financial impact were unknown.
  • May 18, 2026 Invests in MiRus and gets an option on its valve business After clinical and regulatory milestones, Boston Scientific may acquire MiRus’s aortic valve replacement business.

Growing. Revenue grew 69% in 4 years, from $11.9B in FY2021 to $20.1B in FY2025, about 14% a year.

Pulsed-field ablation gains prominence The earlier report listed FARAPULSE pulsed-field ablation among several electrophysiology products; the latest says it has become the unit’s predominant product and revenue component.

Revenue over time
Endoscopy Urology Neuromodulation Interventional Cardiology & Vascular Therapies Watchman Electrophysiology Cardiac Rhythm Management Interventional Oncology & Embolization Global Peripheral Interventions (PI) Reporting Unit Other Global Cardiology Reporting Unit Interventional Cardiology Therapies
$25B$12.5B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support